BLUELINX HOLDINGS INC (BXC) Fundamental Analysis & Valuation

NYSE:BXC • US09624H2085

59.94 USD
-2.18 (-3.51%)
At close: Mar 6, 2026
59.94 USD
0 (0%)
After Hours: 3/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BXC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BXC. BXC was compared to 47 industry peers in the Trading Companies & Distributors industry. The financial health of BXC is average, but there are quite some concerns on its profitability. BXC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. BXC Profitability Analysis

1.1 Basic Checks

  • BXC had positive earnings in the past year.
  • BXC had a positive operating cash flow in the past year.
  • In the past 5 years BXC has always been profitable.
  • Each year in the past 5 years BXC had a positive operating cash flow.
BXC Yearly Net Income VS EBIT VS OCF VS FCFBXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.01%, BXC is in line with its industry, outperforming 40.43% of the companies in the same industry.
  • BXC's Return On Equity of 0.04% is on the low side compared to the rest of the industry. BXC is outperformed by 61.70% of its industry peers.
  • The Return On Invested Capital of BXC (1.69%) is worse than 65.96% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BXC is below the industry average of 9.12%.
Industry RankSector Rank
ROA 0.01%
ROE 0.04%
ROIC 1.69%
ROA(3y)2.18%
ROA(5y)9.78%
ROE(3y)5.3%
ROE(5y)29.53%
ROIC(3y)4.86%
ROIC(5y)14.09%
BXC Yearly ROA, ROE, ROICBXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.01%, BXC is doing worse than 61.70% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BXC has declined.
  • With a Operating Margin value of 1.02%, BXC is not doing good in the industry: 68.09% of the companies in the same industry are doing better.
  • In the last couple of years the Operating Margin of BXC has declined.
  • BXC has a Gross Margin of 15.29%. This is amonst the worse of the industry: BXC underperforms 82.98% of its industry peers.
  • In the last couple of years the Gross Margin of BXC has remained more or less at the same level.
Industry RankSector Rank
OM 1.02%
PM (TTM) 0.01%
GM 15.29%
OM growth 3Y-51.87%
OM growth 5Y-23.7%
PM growth 3Y-89.63%
PM growth 5Y-69.05%
GM growth 3Y-6.52%
GM growth 5Y-0.17%
BXC Yearly Profit, Operating, Gross MarginsBXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BXC Health Analysis

2.1 Basic Checks

  • BXC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for BXC has been reduced compared to 1 year ago.
  • BXC has less shares outstanding than it did 5 years ago.
  • BXC has a worse debt/assets ratio than last year.
BXC Yearly Shares OutstandingBXC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
BXC Yearly Total Debt VS Total AssetsBXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • BXC has an Altman-Z score of 3.36. This indicates that BXC is financially healthy and has little risk of bankruptcy at the moment.
  • With a Altman-Z score value of 3.36, BXC perfoms like the industry average, outperforming 59.57% of the companies in the same industry.
  • The Debt to FCF ratio of BXC is 18.81, which is on the high side as it means it would take BXC, 18.81 years of fcf income to pay off all of its debts.
  • BXC's Debt to FCF ratio of 18.81 is in line compared to the rest of the industry. BXC outperforms 48.94% of its industry peers.
  • BXC has a Debt/Equity ratio of 0.96. This is a neutral value indicating BXC is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.96, BXC perfoms like the industry average, outperforming 40.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF 18.81
Altman-Z 3.36
ROIC/WACC0.17
WACC9.92%
BXC Yearly LT Debt VS Equity VS FCFBXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that BXC has no problem at all paying its short term obligations.
  • BXC has a Current ratio of 4.66. This is amongst the best in the industry. BXC outperforms 95.74% of its industry peers.
  • BXC has a Quick Ratio of 3.12. This indicates that BXC is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 3.12, BXC belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.12
BXC Yearly Current Assets VS Current LiabilitesBXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BXC Growth Analysis

3.1 Past

  • The earnings per share for BXC have decreased strongly by -85.11% in the last year.
  • The earnings per share for BXC have been decreasing by -35.32% on average. This is quite bad
  • Looking at the last year, BXC shows a small growth in Revenue. The Revenue has grown by 0.05% in the last year.
  • The Revenue has been decreasing by -0.94% on average over the past years.
EPS 1Y (TTM)-85.11%
EPS 3Y-68.55%
EPS 5Y-35.32%
EPS Q2Q%-177.05%
Revenue 1Y (TTM)0.05%
Revenue growth 3Y-12.77%
Revenue growth 5Y-0.94%
Sales Q2Q%0.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 85.45% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BXC will show a small growth in Revenue. The Revenue will grow by 5.38% on average per year.
EPS Next Y-41.26%
EPS Next 2Y85.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.9%
Revenue Next 2Y5.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BXC Yearly Revenue VS EstimatesBXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
BXC Yearly EPS VS EstimatesBXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

3

4. BXC Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 63.09, BXC can be considered very expensive at the moment.
  • BXC's Price/Earnings ratio is a bit more expensive when compared to the industry. BXC is more expensive than 63.83% of the companies in the same industry.
  • BXC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.29.
  • The Price/Forward Earnings ratio is 107.41, which means the current valuation is very expensive for BXC.
  • BXC's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. BXC is more expensive than 65.96% of the companies in the same industry.
  • BXC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 63.09
Fwd PE 107.41
BXC Price Earnings VS Forward Price EarningsBXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BXC indicates a somewhat cheap valuation: BXC is cheaper than 68.09% of the companies listed in the same industry.
  • 85.11% of the companies in the same industry are more expensive than BXC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.36
EV/EBITDA 10.3
BXC Per share dataBXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

  • BXC's earnings are expected to grow with 85.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.45%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BXC Dividend Analysis

5.1 Amount

  • No dividends for BXC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BXC Fundamentals: All Metrics, Ratios and Statistics

BLUELINX HOLDINGS INC

NYSE:BXC (3/6/2026, 8:04:00 PM)

After market: 59.94 0 (0%)

59.94

-2.18 (-3.51%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)02-24
Earnings (Next)04-27
Inst Owners99.25%
Inst Owner Change1.62%
Ins Owners2.22%
Ins Owner Change0.01%
Market Cap471.73M
Revenue(TTM)2.95B
Net Income(TTM)219.00K
Analysts77.5
Price Target78.03 (30.18%)
Short Float %6.11%
Short Ratio4.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.66%
Min EPS beat(2)-23.18%
Max EPS beat(2)-10.14%
EPS beat(4)1
Avg EPS beat(4)-14.28%
Min EPS beat(4)-24.67%
Max EPS beat(4)0.88%
EPS beat(8)4
Avg EPS beat(8)9.11%
EPS beat(12)7
Avg EPS beat(12)11.85%
EPS beat(16)10
Avg EPS beat(16)12.41%
Revenue beat(2)1
Avg Revenue beat(2)-0.69%
Min Revenue beat(2)-2.07%
Max Revenue beat(2)0.69%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.07%
Max Revenue beat(4)0.69%
Revenue beat(8)3
Avg Revenue beat(8)-0.71%
Revenue beat(12)3
Avg Revenue beat(12)-2.91%
Revenue beat(16)5
Avg Revenue beat(16)-1.52%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.9%
Valuation
Industry RankSector Rank
PE 63.09
Fwd PE 107.41
P/S 0.16
P/FCF 14.36
P/OCF 7.89
P/B 0.76
P/tB 1.02
EV/EBITDA 10.3
EPS(TTM)0.95
EY1.58%
EPS(NY)0.56
Fwd EY0.93%
FCF(TTM)4.17
FCFY6.96%
OCF(TTM)7.6
OCFY12.67%
SpS375.35
BVpS78.44
TBVpS58.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number40.95
Profitability
Industry RankSector Rank
ROA 0.01%
ROE 0.04%
ROCE 2.25%
ROIC 1.69%
ROICexc 2.37%
ROICexgc 2.83%
OM 1.02%
PM (TTM) 0.01%
GM 15.29%
FCFM 1.11%
ROA(3y)2.18%
ROA(5y)9.78%
ROE(3y)5.3%
ROE(5y)29.53%
ROIC(3y)4.86%
ROIC(5y)14.09%
ROICexc(3y)7.81%
ROICexc(5y)17.95%
ROICexgc(3y)8.79%
ROICexgc(5y)19.65%
ROCE(3y)6.47%
ROCE(5y)18.75%
ROICexgc growth 3Y-56.47%
ROICexgc growth 5Y-25.31%
ROICexc growth 3Y-57.61%
ROICexc growth 5Y-26.66%
OM growth 3Y-51.87%
OM growth 5Y-23.7%
PM growth 3Y-89.63%
PM growth 5Y-69.05%
GM growth 3Y-6.52%
GM growth 5Y-0.17%
F-Score5
Asset Turnover1.91
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF 18.81
Debt/EBITDA 8.51
Cap/Depr 67.49%
Cap/Sales 0.91%
Interest Coverage 0.64
Cash Conversion 85.42%
Profit Quality 15000.5%
Current Ratio 4.66
Quick Ratio 3.12
Altman-Z 3.36
F-Score5
WACC9.92%
ROIC/WACC0.17
Cap/Depr(3y)85.86%
Cap/Depr(5y)87.75%
Cap/Sales(3y)1.05%
Cap/Sales(5y)0.86%
Profit Quality(3y)5219.88%
Profit Quality(5y)3165.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.11%
EPS 3Y-68.55%
EPS 5Y-35.32%
EPS Q2Q%-177.05%
EPS Next Y-41.26%
EPS Next 2Y85.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.05%
Revenue growth 3Y-12.77%
Revenue growth 5Y-0.94%
Sales Q2Q%0.73%
Revenue Next Year3.9%
Revenue Next 2Y5.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.73%
EBIT growth 3Y-58.02%
EBIT growth 5Y-24.42%
EBIT Next Year80.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.11%
FCF growth 3Y-55.16%
FCF growth 5Y-8.53%
OCF growth 1Y-29.81%
OCF growth 3Y-46.94%
OCF growth 5Y1.68%

BLUELINX HOLDINGS INC / BXC FAQ

What is the fundamental rating for BXC stock?

ChartMill assigns a fundamental rating of 4 / 10 to BXC.


What is the valuation status of BLUELINX HOLDINGS INC (BXC) stock?

ChartMill assigns a valuation rating of 3 / 10 to BLUELINX HOLDINGS INC (BXC). This can be considered as Overvalued.


What is the profitability of BXC stock?

BLUELINX HOLDINGS INC (BXC) has a profitability rating of 3 / 10.


How financially healthy is BLUELINX HOLDINGS INC?

The financial health rating of BLUELINX HOLDINGS INC (BXC) is 6 / 10.